- Conditions
- Recurrent Ovarian Cancer
- Interventions
- ChemoID assay, Chemotherapy
- Diagnostic Test · Drug
- Lead sponsor
- Cordgenics, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Jackson, Mississippi • Charleston, West Virginia • Huntington, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 1,320
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sarcoma, Leiomyosarcoma, Malignant Fibrous, Histiocytoma, Angiosarcoma
- Interventions
- gemcitabine, docetaxel, bevacizumab
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Esophageal Cancer, Gastric Cancer
- Interventions
- Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Neoplasms
- Interventions
- Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, Dostarlimab, GSK6097608
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • St Louis, Missouri • The Bronx, New York + 4 more
- Conditions
- Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- androgen-deprivation therapy, docetaxel
- Drug
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 790 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2025
- U.S. locations
- 343
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 243 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- Docetaxel, Placebo, Indoximod, Paclitaxel
- Drug · Other
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 169 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 28
- States / cities
- Gainesville, Florida • Tampa, Florida • Titusville, Florida + 24 more
- Conditions
- Prostate Cancer
- Interventions
- docetaxel
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 2
- States / cities
- Portland, Oregon • Seattle, Washington
- Conditions
- Advanced Cancer
- Interventions
- Docetaxel (Taxotere), Sirolimus (Rapamycin), Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Oropharyngeal Carcinoma (OPC)
- Interventions
- CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel
- Drug
- Lead sponsor
- Corbus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 38
- States / cities
- Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
- Conditions
- Pancreatic Cancer Stage IVA
- Interventions
- Gemcitabine, docetaxel, and capecitabine, Radiation therapy with gemzar
- Drug · Radiation
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, carboplatin, docetaxel, gemcitabine hydrochloride
- Biological · Drug
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Pancreatic Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Adenocarcinoma
- Interventions
- Oxaliplatin, Docetaxel, Leucovorin, Irinotecan, 5-Fluorouracil
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Non Small Cell Lung Cancer, Lung Cancer
- Interventions
- FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
- Drug · Biological · Radiation
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- alvocidib, docetaxel
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Degarelix, Bicalutamide, Ferumoxytol-enhanced MRI imaging
- Drug · Radiation
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Breast Cancer
- Interventions
- cyclophosphamide, docetaxel, doxorubicin hydrochloride, paclitaxel, tamoxifen citrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 30 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Interventions
- green tea and quercetin + docetaxel, Placebo + docetaxel
- Drug
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 99 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Lung Cancer
- Interventions
- filgrastim, docetaxel, vinorelbine tartrate
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1999
- U.S. locations
- 19
- States / cities
- Modesto, California • Washington D.C., District of Columbia • Riverdale, Georgia + 15 more
- Conditions
- Prostate Cancer
- Interventions
- Custirsen, Docetaxel, Prednisone, Dexamethasone
- Drug
- Lead sponsor
- Achieve Life Sciences
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,022 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Los Angeles, California • Marina del Rey, California + 20 more
- Conditions
- Non-small Cell Lung Cancer, Progression of Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Recurrent
- Interventions
- Docetaxel, HyperAcute®-Lung Immunotherapy, Gemcitabine, Pemetrexed
- Drug · Biological
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 24
- States / cities
- Santa Rosa, California • Stamford, Connecticut • Gainesville, Florida + 20 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Docetaxel and GM-CSF
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 4
- States / cities
- San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more
- Conditions
- Relapsed Breast Cancer, Neoplasms, Breast
- Interventions
- Lapatinib, Capecitabine, Docetaxel, nab-Paclitaxel
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 28
- States / cities
- Hot Springs, Arkansas • Anaheim, California • Burbank, California + 25 more
- Conditions
- Prostate Cancer
- Interventions
- nivolumab, docetaxel, enzalutamide, rucaparib, prednisone
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 292 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 19
- States / cities
- Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more
- Conditions
- Breast Cancer
- Interventions
- capecitabine [Xeloda], Taxotere
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 70 Years · Female only
- Enrollment
- 2,611 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas